Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Epic

This article was originally published in The Gray Sheet

Executive Summary

VR and DR implantable cardioverter defibrillators, approved by FDA in September, store 34 joules of energy and can deliver 30 J, while Guidant's competing Prizm II devices store 31 J and deliver 27 J. "The Gray Sheet" incorrectly reported that the Prizm II devices deliver 31 joules (1"The Gray Sheet" Aug. 26, 2002, p. 34)...

You may also be interested in...



St. Jude Epic

Dual-chamber EpicDR and single-chamber Epic VR implantable cardioverter defibrillators, approved via PMA supplement, will compete with Guidant's Prizm II line of small ICDs. Both the DR and VR devices deliver up to 30 joules of energy; the former measures 33 cc and weighs 70 grams, while the latter measures 32 cc and weighs 69 grams. By comparison, the slightly smaller but heavier Prizm II devices deliver 31 joules. A limited release is scheduled for September...

Butterfly Network’s CEO Sees Blank Check Deal As Path To ‘Democratize’ Portable Imaging Platform

Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel